光正眼科(002524) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥216,369,656.47, representing a 16.23% increase compared to ¥186,164,288.40 in the same period last year[5]. - The net loss attributable to shareholders decreased to ¥7,849,394.18, a 78.24% improvement from a loss of ¥36,074,792.53 in the previous year[5]. - The company reported a basic earnings per share of -¥0.02, an improvement of 71.43% from -¥0.07 in the same period last year[5]. - The net loss for the quarter was CNY 7,320,471.91, an improvement from a net loss of CNY 35,990,985.53 in the same period last year, representing a reduction of approximately 79.7%[17]. - The company reported a basic and diluted earnings per share of CNY -0.02, an improvement from CNY -0.07 in the previous period[17]. Cash Flow - The net cash flow from operating activities increased significantly by 271.59%, reaching ¥2,394,751.79 compared to ¥644,464.97 in Q1 2022[10]. - Cash flow from operating activities generated a net inflow of CNY 2,394,751.79, compared to CNY 644,464.97 in the previous period, showing a significant increase[18]. - The net cash flow from financing activities increased by 35.94% to ¥21,502,794.03, compared to ¥15,817,915.33 in Q1 2022, primarily due to increased bank loans[10]. - Cash flow from financing activities yielded a net inflow of CNY 21,502,794.03, up from CNY 15,817,915.33 in the previous period, indicating a growth of 36.5%[19]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,543,863,988.42, a slight decrease of 0.87% from ¥1,557,450,440.86 at the end of the previous year[5]. - Total current assets increased to ¥283,785,069.80 from ¥269,494,229.50 at the beginning of the year, a growth of approximately 5.8%[13]. - Total liabilities decreased slightly to ¥1,276,026,021.73 from ¥1,282,673,217.12, a reduction of approximately 0.5%[15]. - Non-current assets totaled ¥1,260,078,918.62, down from ¥1,287,956,211.36, a decrease of approximately 2.1%[14]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 56,600[11]. - The largest shareholder, Guangzheng Investment Co., holds 25.06% of shares, totaling 129,168,708 shares[11]. - The company has no known related party relationships or concerted action among the top ten shareholders[11]. Operating Costs and Income - Total operating costs amounted to CNY 222,317,216.45, slightly up from CNY 221,611,773.81, indicating a marginal increase of 0.3%[16]. - The company recorded a significant increase in other operating income, which rose by 642.78% to ¥558,983.06 from ¥75,255.30 in the previous year[9]. - The company reported a 939.97% increase in asset disposal income, amounting to ¥395,516.75 compared to ¥38,031.61 in the previous year[9]. Investment and Impairment - The company experienced a credit impairment loss of CNY 33,777.49, a significant recovery from a loss of CNY -193,244.94 in the previous period[17]. - The company recorded an investment loss of CNY -1,220,611.38, worsening from a loss of CNY -543,696.86 in the previous period[16]. - The company experienced a 100% decrease in research and development expenses, which were reported as ¥0.00 compared to ¥309,035.23 in the previous year[9].